Clinical trials: Vasomotor Symptoms (VMS)
Hot Flashes, Breast Cancer
Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer
Due to the fact that majority of breast cancers are estrogen-receptor and/or progesterone receptor positive, tamoxifen and aromatase inhibitors (AIs) are among the mainstay therapies to treat breast cancer.
- Trial name
- VMS (NCT06161792)
- Testing
- 0.8 mg RCN3028
- Where
- 4 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Menopause, Vasomotor Symptoms (VMS)
Waning Moon: A Whole Person Health Intervention Designed by and for Urban Menopausal American Indian/Alaska Native Women
This study tests the feasibility and acceptability of Waning Moon, a culturally tailored menopause health intervention developed in partnership with the Urban Indian Center of Salt Lake (UICSL) for American Indian/Alaska Native…
- Conditions
- Menopause, Vasomotor Symptoms (VMS), Women's Health, Health Disparities
- Trial name
- NCT07713095
- Testing
- Waning Moon
- Volunteers
- 30 people
- Sponsor
- University of Utah
Vasomotor Symptoms (VMS)
Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms
An open-label, long term extension study of MT-8554 in postmenopausal women experiencing moderate to severe vasomotor symptoms who completed Study MT-8554-A01
- Trial name
- NCT03541200
- Testing
- MT-8554
- Where
- 53 sites in United States
- Volunteers
- 190 people
- Sponsor
- Tanabe Pharma America, Inc.
Menopause
Vasomotor Symptoms (VMS) Progesterone Study: Vasomotor Symptoms and Endothelial Function - Trial of Oral Micronized Progesterone
The primary purpose of this study is to determine the effects of a full dose (300 mg at hs) of oral micronized progesterone (OMP) on vasomotor symptoms [VMS] (hot flushes/night sweats), on forearm blood flow and on lipid levels…
- Trial name
- NCT00152438
- Testing
- Oral Micronized Progesterone (Prometrium®)
- Where
- Canada
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Hot Flashes, Hot Flash
Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women
The goal of this study is to evaluate the efficacy of a neurokinin 1,3 antagonist on improving vasomotor symptoms (VMS) and overall menopause symptoms in women between the ages of 40-70.
- Conditions
- Hot Flashes, Hot Flash, Hot Flushes, Menopause, Postmenopause, Hot Flushes and/or Sweats
- Trial name
- NCT07408115
- Testing
- JDS-HF3.0
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Bonafide Health
Vasomotor Symptoms
Goji Berry and Vasomotor Symptoms Pilot Study
The goal of this clinical trial is to compare two forms of goji berry powder-whole goji berry powder and goji juice powder-in peri- and postmenopausal women aged 40-65 years who experience frequent vasomotor symptoms (hot…
- Trial name
- GOJI-VMS (NCT07660315)
- Testing
- Goji Berry Juice Powder, Goji Berry Powder
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Prostate Cancer, Hot Flashes
A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)
The purpose of this study is to find out if patients with prostate cancer who have vasomotor symptoms, commonly called hot flashes, from their Androgen Deprivation Therapy (ADT) will consistently wear a smartwatch device to track…
- Trial name
- BioWEAR (NCT07535541)
- Testing
- VMS logging
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Virginia
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivation therapy.
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent
- Trial name
- Fezo-ADT (NCT06957691)
- Testing
- fezolinetant - reference formulation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Shehzad Basaria, M.D.
Menopause
Hot Flash and Night Sweat Virtual Study
The purpose of this research study is to evaluate the effectiveness of the study product on vasomotor symptoms (VMS) and overall menopause symptoms in healthy women, who are perimenopausal or postmenopausal, and aged 40 - 65.
- Trial name
- NCT06289907
- Testing
- Bonafide-HF3.0
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- Bonafide Health
Vasomotor Symptoms (VMS) Associated With Menopause
An Observational Study to Learn More About Vasomotor Symptoms Burden and Treatment Patterns in Menopausal Women Before and After Participating in OASIS Studies
This is an observational study to learn more about vasomotor symptoms (VSM) burden and treatment patterns in menopausal women before and after participating in OASIS studies.
- Trial name
- OASIS STAR (NCT06949553)
- Testing
- No study intervention
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Perimenopause, Perimenopause-Related Depression
Intra Ovarian Muse Cell Injection for Perimenopause Symptom Relief and Ovarian Function Restoration (MUSE-OVARY)
This observational study examines the safety and effects of injecting Muse cells (a type of naturally occurring stem like cells found in adult tissues such as fat or bone marrow) directly into the ovaries of women aged 28 to 70…
- Conditions
- Perimenopause, Perimenopause-Related Depression, Premature Ovarian Insufficiency, Premature Ovarian Failure (POF)
- Trial name
- MUSE-OVARY (NCT07511660)
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- Healing Hope International
Major Depressive Disorder, Vasomotor Symptoms
Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.
- Trial name
- NCT01353963
- Testing
- desvenlafaxine succinate
- Where
- 3 sites in Philippines
- Volunteers
- 13 people
- Sponsor
- Pfizer
Moderate to Severe Vasomotor Symptoms
A Survey About Trade-offs When Choosing Menopause Treatments
This study is an online survey of women in menopause with moderate to severe hot flashes. Menopause, a normal part of life, is the time after a woman's last period. Hot flashes often occur during menopause.
- Trial name
- NCT05300568
- Testing
- No Intervention
- Where
- United Kingdom
- Volunteers
- 1,465 people
- Sponsor
- Astellas Pharma Europe Ltd.
Vasomotor Symptoms (VMS) Associated With Menopause
An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms in United States
Menopause is a natural stage in a woman's life happening between ages 45 and 55. It is often associated with disruptive symptoms like hot flashes and sleep disturbances that can affect up to 8 out of 10 women and make daily life…
- Trial name
- RELIEF (NCT07490431)
- Testing
- No intervention
- Volunteers
- 2,400 people
- Sponsor
- Bayer
Postmenopausal Symptoms
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
The purpose of this study is to assess the safety \& efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause.
- Trial name
- N30-003 (NCT01361308)
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- 74 sites in United States
- Volunteers
- 614 people
- Sponsor
- Noven Therapeutics
Vasomotor Symptoms
Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).
This Phase 2a randomized, double-blind, placebo-controlled study evaluates the safety and efficacy of asimadoline (TP0052), a peripherally restricted selective kappa-opioid receptor agonist, for moderate to severe menopausal…
- Trial name
- NCT07042516
- Testing
- Asimadoline
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Tioga Pharmaceuticals
Vasomotor Symptoms (VMS)
Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor
This is a Phase 2 proof-of-concept (POC) study designed to determine the effectiveness of Q-122 for the treatment of Vasomotor Symptoms (VMS) versus placebo.
- Trial name
- NCT03518138
- Testing
- Q-122
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 132 people
- Sponsor
- Que Oncology
Vasomotor Symptoms (VMS)
Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen
Open-label, two dose study of Q-122, over a 4 week treatment period to explore the effects of Q-122 in a population of women with a history of breast cancer taking an aromatase inhibitor or tamoxifen.
- Trial name
- NCT04080297
- Testing
- oral capsule of Q-122
- Volunteers
- 21 people
- Sponsor
- Que Oncology
Women in the Menopausal Period
ROSA-B: ALAN Exposure and Brain Health in Midlife Women With VMS
This randomized, parallel-group study will examine how artificial light exposure during nighttime awakenings affects sleep and brain health in midlife women experiencing vasomotor symptoms, such as hot flashes and night sweats.
- Trial name
- NCT07834944
- Testing
- Artificial Light at Night (ALAN) 100 lux, Artificial Light at Night (ALAN) Dim Light
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Hot Flashes
A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause
This study is for women in menopause with hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
- Trial name
- Moonlight 3 (NCT04451226)
- Testing
- Fezolinetant
- Where
- 29 sites in China
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma China, Inc.